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Abstract—Atorvastatin undergoes a self-sensitized photooxygenation by sunlight in water. The main photoproducts, isolated by chromato-
graphic techniques, have been identified by spectroscopic means. They present a lactam ring arising from an oxidation of pyrrole ring and an
alkyl/aryl shift. A mechanism involving singlet oxygen addition and an epoxide intermediate is suggested.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Atorvastatin calcium is one of the most prescribed drugs in
the US and in Europe.1 It is a synthetic lipid-lowering agent
and is widely used in the prevention of cardiovascular
events. It is an inhibitor of 3-hydroxy-3-methylglutaryl-co-
enzyme A (HMG-CoA) reductase, an enzyme that catalyzes
the conversion of HMG-CoA to mevalonate, an early and
rate-limiting step in cholesterol biosynthesis. Moreover, re-
cently it has been observed that atorvastatin, like other statin
drugs, can be efficient against Alzheimer’s disease.2 Less
than 5% of a dose of atorvastatin is recovered in urine fol-
lowing oral administration. The presence of atorvastatin in
sewage effluents and surface waters has been observed in
concentration at mg/l levels.3 The presence of pharmaceuti-
cals in surface and ground waters is an increasingly relevant
issue in environmental chemistry.4 These substances enter
into the aquatic environment, and thus they are potential
pollutants for the aquatic ecosystem, possibly with adverse
effects on aquatic organisms. The occurrence of pharmaceu-
ticals in surface waters has been extensively reviewed, but
data on the fate of these xenobiotics in the environment
are still limited. These chemicals can be transformed
through abiotic processes (hydrolysis, photolysis) into dif-
ferent products, and many searches are now addressed to
the identification of these transformation products.5–8
In this context, we decided to study the photo-induced trans-
formation processes of atorvastatin in water. Particular atten-
tion has been focused on the isolation and characterization of
its main photoproducts as well as to the elucidation of the
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2. Results and discussion
Preliminary experiments showed that the drug was recov-
ered unchanged by keeping it in the dark in aqueous solution
(at different pHs) even after 30 days.
The photochemical behavior of atorvastatin in water was
then studied under different conditions. First of all a solution
of atorvastatin (10 mM) was exposed to natural sunlight. The
1H NMR analysis of the irradiation mixture showed the
presence of the drug and several products. In order to get
amounts of photoproducts suitable for spectroscopic analy-
ses, a series of irradiation experiments were performed on
a preparative scale. A dispersion of the drug (80 mg/l) was
irradiated by a solar simulator and the irradiation was mon-
itored by RP-TLC analysis. After 14 days, the irradiation
mixture was analyzed by NMR spectroscopy revealing that
atorvastatin was completely transformed. The same photo-
products as in sunlight irradiation were observed by NMR
and RP-TLC analyses. The main photoproducts were then
separated by chromatographic techniques employing several
stationary and mobile phases. Repeated column/TLC chro-
matographies and preparative HPLC of the mixture were
necessary to isolate compounds 2–5 (Fig. 1).9 Careful
NMR analysis of the fractions containing 5 showed the pres-
ence of very close double signals, which were attributed to
two diasteromers. The latter could be separated as methyl es-
ters after performing a methylation reaction with CH2N2.
10
The structures for all compounds were elucidated by NMR
techniques (COSY, TOCSY, HSQC, HMBC, NOESY) and
MALDI-MS experiments.
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the MALDI-MS spectrum suggesting, along with the ele-
mental analysis, a molecular formula C33H34FN2O6. The
UV spectrum revealed a band at 203 nm. In the 1H NMR
spectrum, 14 aromatic protons were present in the 7.00–
7.40 ppm range; furthermore three methine at d 4.17, 3.76,
and 3.27, eight methylene protons at d 3.76, 2.40, 1.85,
and 1.66, and two methyls at d 1.45 were in the aliphatic re-
gion. The 13C NMR spectrum showed 27 carbon signals. The
DEPT spectrum showed two methyls, four methylenes, and
eleven methines. A close inspection of the 1H and 13C NMR
spectra of 2 by DEPT and HSQC experiments and compari-
son with the spectral data for atorvastatin 1 revealed the pres-
ence of the following functionalities: three carbonyl groups,
one quaternary sp3-carbon (C-10), three aliphatic methines
(C-3, C-5, and C-14), the first two bearing oxygen, four
aliphatic methylene carbons (C-2, C-4, C-6, and C-7), two
methyls (C-15 and C-16), two quaternary sp2-carbons
(C-11 and C-12), two monosubstituted aromatic rings (C-
10–C-60, C-100–C-600), and one disubstituted aromatic ring
(C-1000–C-6000). The connection of these functional groups
was determined on the basis of 1H–1H COSY and HMBC
correlations. Long-range correlations from the H-7 protons
at d 3.76 to the carbonyl carbon (d 181.4) and C-12 (d
153.4), the H-14 proton at d 3.27 to the C-11 (d 119.3) and
C-12 quaternary carbons, the latter also correlated with
H-14/H-15 methyls in the HMBC spectrum indicating the
presence of 1-H-pyrrol-2(3H)-one. The correlation from
H-200/H-600 and H-2000/H-6000 protons (d 7.30 and 7.34) to the
C-10 (d 66.6) indicated the linkage of two phenyl groups
at the sp3 quaternary carbon. These correlations were consis-
tent with structure 2.
Compound 3 showed a molecular peak at m/z 575 [M+H]+ in
the ESI-MS spectrum suggesting, along with the elemental
analysis, a molecular formula C33H34FN2O6. The UV spec-
trum revealed a band at 204 nm. The 13C NMR spectrum
showed 27 carbon signals. The DEPT spectrum showed
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Figure 1. Structure of atorvastatin and photoproducts 2–5.two methyls, four methylenes, and eleven methines. A close
inspection of the 1H and 13C NMR spectra of 3 by DEPT and
HSQC experiments and comparison with the spectral data
for the atorvastatin 1 revealed the presence of the following
functionalities: three carbonyl groups, one quaternary sp3-
carbon (C-11), three aliphatic methines (C-3, C-5, and
C-14), two of them bearing oxygen, four aliphatic methylene
carbons (C-2, C-4, C-6, and C-7), two methyls (C-15 and
C-16), two quaternary sp2-carbons (C-9 and C-10), two
monosubstituted aromatic rings (C-10–C-60, C-100–C-600),
and one disubstituted aromatic ring (C-1000–C-6000). The con-
nection of these functional groups was determined on the
basis of 1H–1H COSY and HMBC correlations. Long-range
correlations from the H-7 protons at d 3.79 and 3.56 to the
carbonyl carbon (d 178.2) and C-9 (d 140.4), the H-14 proton
at d 2.67 to C-10 (120.0), C-11 (d 69.9), C-12, and C-13;
C-11 also correlated with H-14/H-15 methyls in the
HMBC spectrum indicating the presence of 1-H-pyrrol-
2(3H)-one. These correlations were consistent with the
structure 3 as depicted.
According to the d lactone structure, a molecular ion at m/z
579 [M+Na]+ in the ESI-MS was present for compound 4.
The 1H–1H COSY experiment showed a correlation series
beginning with signal of a methylene at d 3.79 and 3.56 as-
signed to H-7 to methylene at d 1.85, which in turn was cou-
pled with methine at d 4.52. This latter was correlated to
methylene at d 1.77, which in turn was coupled with methine
at d 4.16 correlated with methylene at d 2.59 and 2.42. Two
doublets were attributed to two methyls at d 1.16 and 0.95
correlated to methine at d 2.78. The 13C NMR spectrum of
4 showed 27 carbon signals due to two methyls, four methyl-
enes, eleven methines, and ten quaternary carbons. An
HMQC experiment allowed to assign the protons to the cor-
responding carbons. In the HMBC spectrum, H-7 protons
were correlated with C-5, C-9, and C-12, while the H-14 pro-
ton was correlated with the C-10, C-11, C-12, C-13, C-15,
and C-16. The multiplet at d 4.52 (H-5) was correlated
with C-1 and C-3, while H-3 was correlated with C-1, C-2,
and C-5, thus completely dating the structure of 4.
Compound 5 was a ca. 1:1 mixture of diasteromers, which
were separated and characterized as methyl esters. One iso-
mer of 5 showed a molecular peak at m/z 587 [M+H]+ in the
ESI-MS spectrum suggesting, along with the elemental
analysis, a molecular formula C34H35FN2O6. The
1H NMR
spectrum showed the presence of one aromatic ring with
three coupled protons, which were also coupled with fluo-
rine atom, and resulted as two double doublet at d 8.51
(H-6000), 8.45 (H-3000) and a double double doublet at d 7.45.
Furthermore, four protons of a 1,2 disubstituted aromatic
ring at d 8.76 (H-600), 8.60 (H-300), as doublets and at d 7.69
(H-500) and 7.60 (H-400) as triplets and a phenyl group
(H-20–H-60) were present in the aromatic region. The ali-
phatic region of 1H NMR spectrum presented the usual C7
chain, the isopropyl group, and a methyl. In the 13C NMR
spectrum, 30 carbon signals were present, and the DEPT ex-
periment evidenced three methyls, four methylenes, and thir-
teen methines. The 1H and 13C resonances were assigned by
combination of COSY, DEPT, HMQC, and HMBC experi-
ments. In particular, the HMBC spectrum showed cross-
peaks of both the H-7 and H-14 with carbonyl (C-12), the first
was correlated with C-5 and C-9, both the H-14 and the
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C-10 and C-13 carbons. These data indicated the presence
of 1-H-pyrrol-2(3H)-one. In the HMBC spectrum, correla-
tions between H-6000 and C-9, C4000, and C3000 carbons, H-200
and C-10, C-200, and C-400 carbons, and H-300 and C-2000 and
C-500 indicate a phenathrene unit.
The other isomer of 5 had the molecular formula
C34H35FN2O6 as deduced from the molecular peak at m/z
587 [M+H]+ in the ESI-MS spectrum. The general features
of the NMR spectra closely resembled those of its isomer,
except for the shift of the methyl signals and 600 methine.
As shown in Figure 1, all photoproducts characterized arise
from an oxidation of pyrrole ring and an alkyl/aryl shift with
formation of a lactam ring. In addition, compounds 4 and 5
derive from 3 via lactonization and cyclization, respectively.
To get information on the possible pathways leading to
compounds 2–5, irradiation experiments were run under dif-
ferent conditions, and to shorten the reaction times UV-lamp
(Pyrex filter) was used as light source. With this lamp, the
drug was converted to compounds 2–5 in 8 h (w70%).
When the irradiation was carried out under argon atmo-
sphere, the drug was recovered unreacted, confirming that
O2 was directly involved in the phototransformation. Degra-
dation slowed down in the presence of a radical inhibitor as
3-tert-butyl-4-anisole (BHA), while it was completely in-
hibited by sodium azide (NaN3), a well-known quencher
of singlet oxygen. Moreover, when the photooxygenation
was carried out in the presence of Rose Bengal, a typical sin-
glet oxygen sensitizer, the reaction was complete already
after 8 h. NMR analysis and TLC showed that atorvastatin
was transformed in compounds 2–5 as main photoproducts.
These data suggest that singlet oxygen may be involved in
the photodegradation of the drug and, hence, a Type II
(singlet oxygen-mediated) photooxygenation may occur.11
It is well known that pyrroles are good substrates for singlet
oxygen. They often give a mixture of products derived both
from 2,5- and 2,3-oxygen addition as well as from hydroper-
oxides or zwitterionic intermediates, depending on the reac-
tion conditions and on the substituents, and the question of
primary adducts is still an open point.12 Anyhow, hydroxy-
lactams have sometime been found as photooxygenation
products from a- or a,a0-unsubstituted pyrroles.12 So, on
the basis of experimental results and literature data a plausi-
ble mechanistic interpretation is reported in Scheme 1. The
first step should be an energy transfer from the excited drug
to oxygen producing singlet oxygen. Then, a 2,3-oxygen
addition to the pyrrole moiety probably occurs to give
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Scheme 1. Suggested pathways for compounds 2 and 3.perepoxides 6 or 7, which evolve to epoxides 8 or 9.13 Migra-
tion of the aryl or alkyl moiety gives pyrrolones 2 or 3,
respectively.14
Epoxides 8 and 9 were not detected in our experiments,
probably due to their easy rearrangement to the correspond-
ing carbonyl compounds.15 In order to prove the involve-
ment of these intermediates, an oxidation reaction of
atorvastatin was carried out by using dimethyldioxirane
(DMD). This compound is a well-known epoxidizing agent
for diverse unsaturated substrates from alkenes to aromatic
compounds, and it reacts with N-acylindoles to give the cor-
responding epoxides that open to form 2-indolinones as
rearranged products.16 The reaction of 1 with DMD was
carried out in acetone and after 4 h the reaction mixture
showed the presence of compounds 2 and 3.
Compounds 4 and 5 seem to arise from further modification
of compound 3. Lactonization of a six-membered ring of the
dihydroxy heptanoic acid side chain affords compound 4,
while phenantrene 5 is formed through a well-known17 pro-
cess in the photochemistry of stilbene-like compounds. In
particular, it would be formed by photochemical electro-
cyclization followed by oxidation, under aerobic conditions,
of the dihydrophenantrene intermediate.
3. Conclusions
In conclusion, atorvastatin has been found to be sensitive to
sunlight under aerobic conditions and the main photoprod-
ucts have been isolated and fully characterized by spectral
means (NMR and MS). This behavior agrees with the obser-
vation reported in two recent works that atorvastatin is
phototransformed with a quantum yield for direct photolysis
of 4.5103.9
Our data evidenced that in the presence of light and oxygen,
the drug is able to act as a self-sensitizer and generate singlet
oxygen,18 and this observation appears of particular interest
in the field of photosensitization phenomena by drugs.19
4. Experimental
4.1. Chemicals
Atorvastatin calcium was obtained from KEMPROTEC
Limited. This and all the other products were used without
further treatment: Rose Bengal (RB, Aldrich), NaN3 (Carlo
Erba). Solutions and suspensions of atorvastatin were
prepared using Milli Q water. All other solvents were of
HPLC grade.
4.2. General procedures
HPLC experiments were carried out on an Agilent 1100
HPLC system equipped with an UV detector, the column
used was a RP-18 column (Luna Prep C-18, 10 mm,
25010 mm). Nuclear magnetic resonance (NMR) spectra
were recorded at 500 MHz for [1H] and 125 MHz for [13C]
on a Fourier Transform NMR Varian 500 Unity Inova spec-
trometer and at 400 MHz for [1H] and 100 MHz for [13C] on
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evidenced by DEPT experiments. The proton couplings were
evidenced by 1H–1H COSY experiments. The heteronuclear
chemical shift correlations were determined by HMQC and
HMBC pulse sequences. 1H–1H proximities through space
within a molecule were determined by NOESY. Matrix
assisted laser desorption ionization (MALDI) mass spectra
were recorded using a Voyager-DE MALDI-TOF mass spec-
trometer. Electrospray mass spectra were recorded using
a WATERS Z-Q mass spectrometer equipped with an elec-
trospray ionization (ESI) probe operating in positive or neg-
ative ion mode. The scan range was 80–2000 m/z. UV–vis
spectra were recorded in MeOH on a Perkin–Elmer Lambda
7 spectrophotometer. IR spectra were recorded in CH2Cl2 on
a Nicolet 5700 FT-IR spectrometer. Reverse phase liquid
chromatography was performed over Lichroprep RP-18
resin (Merck). Analytical TLC was performed on precoated
Merck aluminum sheet (DC-Alufolien Kielselgel 60 F254,
0.2 mm) or RP-18 F254 plates with 0.2 mm film thickness.
The spots were visualized by UV light or by spraying with
H2SO4/AcOH/H2O (1:20:4). The plates were then heated
for 5 min at 110 C. Prep. TLC was performed on a Merck
Kiesegel 60 F254 plates, with 0.5 or 1 mm film thickness.
4.3. Irradiation conditions
Irradiation experiments were performed with a 150 W solar
simulator Oriel equipped with a Xenon lamp (spectral output
200–2400 nm) on a suspension of atorvastatin calcium
(40 mg) in Milli Q water (500 ml), or solution 10 mM, in
a Pyrex beaker for 14 days at room temperature.
An analogous preparation of atorvastatin calcium was
exposed to sunlight for 14 days (on September in Naples)
in an open Pyrex flask.
In an attempt to gain some mechanistic information, other
irradiation experiments were performed using a photoreactor
equipped with a 500 W high-pressure mercury lamp
(through a Pyrex filter).
In a typical procedure, a suspension of atorvastatin calcium
(10 mg in 20 ml of water) in the presence of a sensitizer (mo-
lar ratio atorvastatin:sens ¼ 10:1 or as otherwise indicated)
in an open Pyrex tube was irradiated at room temperature
under stirring at a distance of 15 cm from the lamp.
NaN3 and the pharmaceutical was used in a 1:3 molar ratio.
In the experiment carried out under argon atmosphere, the
suspension was saturated with the gas for 30 min before
irradiation and then kept closed.
4.4. Photoproduct isolation
The suspension after 14 days irradiation by solar simulator
was dried under vacuum, and the acetone-soluble reaction
mixture (40 mg) was separated by silica-gel TLC eluting
with the organic phase of the mixture AcOEt/EtOH/H2O
(3:1:5) to give five fractions.
Fractions 2 and 4 were pure photoproduct 2 (11 mg) and 3
(4 mg), while fractions 1, 3, and 5 were mixtures of several
products.Fraction 3 (8 mg) was chromatographed on silica-gel TLC
eluting with CH2Cl2/MeOH (95:5) to afford photoproduct
4 (4 mg) and the diastereomeric mixture of 5 in small
quantities.
In order to obtain greater quantities of these products,
a suspension of atorvastatin was kept at sunlight exposure
(40 mg) for 14 days. The irradiation mixture was dried under
vacuum and chromatographed on a RP-18 resin open column
eluting with CH3CN/H2O (1:1) to afford four fractions (A, B,
C, and D). Fraction D was a crude mixture of photoproducts
5 (8 mg). To achieve the separation of the diasteroisomeric
compounds, the mixture was subjected to methylation with
excess of diazomethane in ether solution. Methylation was
quantitative and the resulting mixture was separated on
a RP-18 HPLC column eluting with CH3CN/H2O (1:1).
4.5. Reaction with dimethyldioxirane
A solution of DMD (w0.5–0.12 M) in acetone was obtained
according to literature procedure.20 To a solution of atorvas-
tatin calcium (5 mg) in acetone (10 ml), 5 ml of the DMD
solution (w0.5–0.12 M) in acetone were added under
stirring. The reaction mixture was dried under vacuum and
analyzed by 1H NMR spectroscopy. NMR analysis
evidenced the formation of photoproducts 3 and 4.
4.6. Spectral data
4.6.1. Atorvastatin (1). UV lmax (CH3OH) nm: 206 (log 3
7.0); nmax (CHCl3) 2964, 1723, 1658, 1607 cm
1; ESI-MS
m/z (%): 597 (12), 581 (25), 559 (85), 415 (100); dH
(500 MHz, CD3OD) 7.55–6.98 (14H), 4.18 (2H, m, H-7a
and H-3), 3.93 (1H, m, H-7b), 3.67 (1H, m, H-5), 3.40
(1H, m, H-14), 2.36 (1H, dd, J 10.2, 4.8 Hz, H-2a), 2.26
(1H, dd, J 10.2, 2.4 Hz, H-2), 1.70 (2H, m, H-6), 1.60 (1H,
m, H-4), 1.50 (6H, d, J 7.2 Hz, H-15, H-16), 1.41 (1H, m,
H-4); dC (125 MHz, CD3OD) 181.5, 170.0, 164.5, 140.5,
139.8, 137.5, 135.5, 131.5, 130.6, 130.1, 129.4, 128.3,
126.6, 124.0, 122.0, 119.8, 117.2, 117.0, 69.6, 45.5, 44.7,
42.5, 42.0, 28.1, 23.3.
4.6.2. Compound 2. Colorless oil; UV lmax (CH3OH) nm:
203 (log 3 11.9); nmax (CHCl3) 3040, 2920, 2854, 1712,
1602, 1097 cm1; ESI-MS m/z (%): 613 (15), 597 (20),
575 (100). Anal. calcd for C33H35FN2O6: C, 68.97, H,
6.14, F, 3.31, N, 4.87. Found: C, 76.09, H, 6.05, F, 3.28,
N, 4.84; dH (500 MHz, CD3OD) 7.40–7.00 (14H), 4.17
(1H, m, H-3), 3.76 (3H, m, H-5, H-7), 3.27 (1H, m, H-14),
2.40 (2H, m, H-2), 1.85 (2H, m, H-6), 1.66 (2H, m, H-4),
1.45 (6H, d, J 6.5 Hz, H-15, H-16); dC (125 MHz,
CD3OD) 181.4 (C-9), 176.8 (C-1), 166.2 (C-13), 164.0
(C-4000), 153.4 (C-12), 141.3 (C-1000), 139.3 (C-10), 132.4
(C-100), 130.7, 130.2, 129.5, 126.2, 122.1, 119.3 (C-11),
116.7, 116.6, 68.7 (C-5), 68.3 (C-3), 66.6 (C-10), 45.0
(C-4), 43.9 (C-2), 39.6 (C-7), 37.7 (C-6), 28.5 (C-14),
21.4, 21.2 (C-15, C-16).
4.6.3. Compound 3. Amorphous white powder; UV lmax
(CH3OH) nm: 204 (log 3 12.5); nmax (CHCl3) 2957, 2924,
2855, 1714, 1712, 1600, 1364, 1088 cm1; ESI-MS m/z
(%): 613 (10), 597 (25), 575 (100). Anal. calcd for
C33H35FN2O6: C, 68.97, H, 6.14, F, 3.31, N, 4.87. Found:
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7.53 (2H, d, J 8.0 Hz), 7.36 (4H, m), 7.12 (8H, m), 4.02
(1H, m, H-3), 3.79 (1H, m, H-7a), 3.72 (1H, m, H-5), 3.56
(1H, m, H-7b), 2.67 (1H, m, H-14), 2.38 (2H, m, H-2),
1.48–1.68 (4H, m, H-4, H-6), 1.18 (3H, d, J 6.8 Hz, H-15),
0.92 (3H, d, J 6.8 Hz, H-16); dC (125 MHz, CD3OD)
178.2 (C-12), 175.8 (C-1), 168.6 (C-13), 164.0 (C-4000),
140.4 (C-9), 135.3, 134.0, 132.0, 131.9, 130.3, 129.6,
128.8, 128.2, 126.4, 123.4, 120.0, 117.4, 117.2, 69.9
(C-11),69.6 (C-5), 68.6 (C-3), 45.0 (C-4), 44.1 (C-2), 39.9
(C-7), 36.2 (C-6), 33.5 (C-14), 18.8 (C-15), 17.9 (C-16).
4.6.4. Compound 4. Amorphous white powder; UV lmax
(CH3OH) nm: 202 (log 3 0.42). nmax (CHCl3) 2925, 2854,
1730, 1700, 1605, 1428, 1236, 1157, 1074 cm1; MALDI-
MS m/z (%): 579 (30), 556 (100). Anal. calcd for
C33H35FN2O6: C, 71.21, H, 5.98, F, 3.41, N, 5.03. Found:
C, 71.18, H, 6.00, F, 3.39, N, 5.00; dH (500 MHz, CD3OD)
7.50–7.24 (6H, m), 7.16 (8H, m), 4.52 (1H, m, H-5), 4.16
(1H, m, H-3), 3.79 (1H, m, H-7a), 3.56 (1H, m, H-7b), 2.78
(1H, m, H-14), 2.59 (1H, dd, J 3.9, 17.6 Hz, H-2a), 2.42
(1H, dd, J 17.6 Hz, H-2a), 1.85 (2H, m, H-6), 1.77 (2H, m,
H-4), 1.16 (3H, d, J 7.0 Hz, H-15), 0.95 (3H, d, J 7.0 Hz,
H-16); dC (125 MHz, CD3OD) 178.2 (C-12, C-13), 172.5
(C-1), 162.5 (C-4000), 143.7 (C-9), 138.0, 135.1, 134.5,
134.1, 132.2, 130.3, 130.1, 129.6, 128.8, 126.6, 123.8,
122.2 (C-10), 117.4, 117.2, 76.1 (C-5), 63.6 (C-3), 39.4
(C-2, C-7), 35.6 (C-6), 33.1 (C-14), 18.8 (C-15), 17.6 (C-16).
4.6.5. Compound 5. Colorless oil (one diastereomer); UV
lmax (CH3OH) nm: 204, 238, 332; nmax (CHCl3) 3481,
3334, 3010, 2932, 1717, 1697, 1601, 1450, 1314,
1163 cm1; ESI-MS m/z (%): 609 (44), 587 (100). Anal.
calcd for C33H35FN2O6: C, 69.61, H, 6.01, F, 3.24, N,
4.78. Found: C, 69.58, H, 5.98, F, 3.25, N, 4.75; dH
(500 MHz, CD3OD) 8.76 (1H, d, J 9.0 Hz, H-6
00), 8.60
(1H, d, J 9.0 Hz, H-300), 8.51 (1H, dd, J 5.5, 9.5 Hz,
H-6000), 8.45 (1H, dd, J 2.0, 11.5 Hz, H-3000), 7.69 (1H, t, J
7.0 Hz, H-500), 7.60 (1H, t, J 7.0 Hz, H-400), 7.49 (2H, d, J
8.0 Hz, H-20, H-60), 7.45 (1H, ddd, J 2.0, 9.5, 11.0 Hz,
H-5000), 7.29 (2H, t, J 8.0 Hz, H-30, H-50), 7.09 (1H, t, J
8.0 Hz, H-40), 4.67 (1H, m, H-7a), 4.45 (1H, m, H-7b),
4.20 (1H, m, H-3), 4.02 (1H, m, H-5), 3.42 (1H, m, H-14),
2.44 (2H, m, H-2), 2.15 (1H, m, H-6a), 2.05 (1H, m,
H-6b), 1.74 (2H, m, H-4), 1.35 (3H, d, J 6.5 Hz, H-15),
0.66 (3H, d, J 6.5 Hz, H-16); dC (125 MHz, CD3OD)
179.2 (C-12), 173.0 (C-1), 165.5 (C-13), 162.0 (C-4000),
137.6 (C-10), 137.0 (C-9), 134.7 (C-2000, C-100), 129.1 (C-30,
C-50), 129.0 (C-300), 128.0 (C-20, C-60), 128.6 (C-500), 127.1
(C-600), 125.5 (C-6000), 125.2 (C-400), 124.9 (C-40), 123.4
(C-300), 120.7 (C-20, C-60), 120.0 (C-10), 118.2 (C-1000),
116.1 (C-5000), 109.5 (C-3000), 69.3 (C-5), 69.0 (C-3), 66.4
(C-11), 42.0 (C-4), 41.4 (C-2), 40.0 (C-7), 37.2 (C-6), 35.6
(C-14), 18.2 (C-16), 17.7 (C-15). The other diastereomer.
Colorless oil; UV lmax (CH3OH) nm: 204, 238, 332; nmax
(CHCl3) 3481, 3334, 3010, 2932, 1717, 1697, 1601, 1450,
1314, 1163 cm1; ESI-MS m/z (%): 609 (44), 587 (100).
Anal. calcd for C33H35FN2O6: C, 69.61, H, 6.01, F, 3.24,
N, 4.78. Found: C, 69.58, H, 5.98, F, 3.25, N, 4.75; dH
(500 MHz, CD3OD) 8.68 (1H, d, J 8.0 Hz, H-6
00), 8.58
(1H, d, J 8.0 Hz, H-300), 8.49 (1H, dd, J 5.5, 9.5 Hz,
H-6000), 8.46 (1H, dd, J 2.0, 11.0 Hz, H-3000), 7.67 (1H, t, J
7.5 Hz, H-500), 7.59 (1H, t, J 7.5 Hz, H-400), 7.45 (2H, d, J8.5 Hz, H-20, H-60), 7.45 (1H, obscured, H-5000), 7.25 (2H,
t, J 8.5 Hz, H-30, H-50), 7.07 (1H, t, J 8.0 Hz, H-40), 4.65
(1H, m, H-7a), 4.44 (1H, m, H-7b), 4.32 (1H, m, H-3),
4.18 (1H, m, H-5), 3.42 (1H, m, H-14), 2.48 (2H, m, H-2),
2.08 (2H, m, H-6), 1.68 (2H, m, H-4), 1.38 (3H, d, J
7.0 Hz, H-15), 0.63 (3H, d, J 7.0 Hz, H-16); dC (125 MHz,
CD3OD) 177.8 (C-12), 173.6 (C-1), 166.2 (C-13), 162.3
(C-4000), 137.6 (C-10), 137.0 (C-9), 134.5 (C-2000, C-100),
129.0 (C-30, C-50), 128.8 (C-300), 128.1 (C-20, C-60, C-500),
126.5(C-600, C-6000), 125.4 (C-40, C-400), 124.8 (C-300), 123.4
(C-20, C-60), 119.3 (C-10), 118.2 (C-1000), 116.1 (C-5000),
109.5 (C-3000), 70.5 (C-5), 69.1 (C-3), 52.1 (C-11), 42.4
(C-4), 41.5 (C-2), 40.9 (C-7), 37.6 (C-6), 35.0 (C-14), 18.4
(C-16), 17.5 (C-15).
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